Research Tree Research Tree Logo

  • Try our Investor Tool
  • Login
  • Sign Up

Research Tree Logo

  • Login
  • Sign Up
  • Features
  • Pricing
  • Reg.News
  • Contact
  • Try our Investor Tool
  • Login
  • Sign Up
  • Providers
  • Companies
⨯
LIVE

Event in Progress:

Join Here ×
  • Providers
  • Companies
⨯
  • Features
  • Pricing
  • Event Hub
  • Reg.News
  • Short Interest
  • Contact
Companies >
UK >
Pharmaceuticals >
HUTCHMED (China) Limited >
Research >
Strategic collaboration for Tazverik in Greater China

working
  • 10 Aug 2021

Strategic collaboration for Tazverik in Greater China


HUTCHMED (China) Limited (HCM:LON) | 231 32.3 6.4% | Mkt Cap: 1,997m


  • Trinity Delta
    • Franc Gregori | Lala Gregorek

    • 2 pages

Pharmaceuticals image


 
Pharmaceuticals image


▪ HUTCHMED has announced a strategic collaboration with Epizyme (NASDAQ: EPZM) to develop and commercialise Tazverik (tazemetostat) for the Greater China area. HUTCHMED will pay Epizyme $25m upfront, up to $110m in clinical and regulatory milestones (across up to eight oncology indications), and up to $175m in commercialisation milestones. Royalties on net sales in Greater China (mainland China, Hong Kong, Macau, and Taiwan) are tiered, ranging from a midteens to low-twenties percentage. HUTCHMED also receives a four-year warrant to acquire up to $65m of Epizyme shares at $11.50/share. The upfront and early milestone payments will come from existing cash resources, with later milestones expected to be paid out of future cash flows (including Tazverik’s). ▪ Tazverik (tazemetostat) is a highly selective methyltransferase inhibitor of EZH2, a key regulator of cancer initiation and progression, including drug resistance and immune evasion. It was FDA approved under accelerated approval for metastatic or locally advanced epithelioid sarcoma (ES) and relapsed/refractory follicular lymphoma (FL) with the relevant EZH2 mutation. The mode of action makes it particularly attractive as part of potential therapy combinations. Epizyme is developing Tazverik across four areas including lymphomas and B-cell malignancies, mutationally defined tumours, treatment-resistant tumours, and in augmenting response to immunotherapy. ▪ HUTCHMED will undertake the necessary clinical trials to file for approval of tazemetostat for ES, FL, and diffuse large b-cell lymphoma (DLBCL) in Greater China. It will conduct the China element of the EZH-302 global registration R2 (Revlimid and rituximab) combination trial in second-line FL. HUTCHMED will also conduct and fund further studies in Greater China and participate in the relevant elements of any global trial programmes. HUTCHMED will manufacture and commercialise Tazverik through its newly constructed production facilities and expanding China Oncology sales team.

Sign up for free to access

Get access to the latest equity research in real-time from 12 commissioned providers.

Get access to the latest equity research in real-time from 12 commissioned providers.


Get Started
Already a member? Log in here
See all the research we have on this company.

Strategic collaboration for Tazverik in Greater China


HUTCHMED (China) Limited (HCM:LON) | 231 32.3 6.4% | Mkt Cap: 1,997m


  • Published: 10 Aug 2021
  • Author: Franc Gregori | Lala Gregorek
  • Pages: 2
  • Trinity Delta


▪ HUTCHMED has announced a strategic collaboration with Epizyme (NASDAQ: EPZM) to develop and commercialise Tazverik (tazemetostat) for the Greater China area. HUTCHMED will pay Epizyme $25m upfront, up to $110m in clinical and regulatory milestones (across up to eight oncology indications), and up to $175m in commercialisation milestones. Royalties on net sales in Greater China (mainland China, Hong Kong, Macau, and Taiwan) are tiered, ranging from a midteens to low-twenties percentage. HUTCHMED also receives a four-year warrant to acquire up to $65m of Epizyme shares at $11.50/share. The upfront and early milestone payments will come from existing cash resources, with later milestones expected to be paid out of future cash flows (including Tazverik’s). ▪ Tazverik (tazemetostat) is a highly selective methyltransferase inhibitor of EZH2, a key regulator of cancer initiation and progression, including drug resistance and immune evasion. It was FDA approved under accelerated approval for metastatic or locally advanced epithelioid sarcoma (ES) and relapsed/refractory follicular lymphoma (FL) with the relevant EZH2 mutation. The mode of action makes it particularly attractive as part of potential therapy combinations. Epizyme is developing Tazverik across four areas including lymphomas and B-cell malignancies, mutationally defined tumours, treatment-resistant tumours, and in augmenting response to immunotherapy. ▪ HUTCHMED will undertake the necessary clinical trials to file for approval of tazemetostat for ES, FL, and diffuse large b-cell lymphoma (DLBCL) in Greater China. It will conduct the China element of the EZH-302 global registration R2 (Revlimid and rituximab) combination trial in second-line FL. HUTCHMED will also conduct and fund further studies in Greater China and participate in the relevant elements of any global trial programmes. HUTCHMED will manufacture and commercialise Tazverik through its newly constructed production facilities and expanding China Oncology sales team.

More Content

More Content

Trinity Delta Lighthouse: HUTCHMED

Companies: HUTCHMED (China) Limited

Trinity Delta

Hybridan - Small Cap Wrap

Companies: AVG COG FISH FUM LRM NWF PLI SCH TMT AVCT BIDS AKR 13

Hybridan

HUTCHMED - Termination of coverage

Companies: HUTCHMED (China) Limited

Edison

Stellar evolution

Companies: HUTCHMED (China) Limited

Edison

Hong Kong listing number 13 is a potent symbol

Companies: HUTCHMED (China) Limited

Trinity Delta

Useful Links

  • Features
  • Pricing
  • RNS/Newswires Feeds
  • Providers Hub
  • Company Hub

Account

  • Login
  • Free Trial - Join Now
  • Contact
Follow us on Linkedin Follow us on Twitter

Share:

Copyright © 2022 Research Tree | All Rights Reserved. | Terms of Service and Privacy Policy and Statement on Cookies

Research Tree will never share your details with third parties for marketing purposes. Research Tree distributes research documents that have been produced and approved by Financial Conduct Authority (FCA) Authorised & Regulated firms as well as relevant content from non-authorised sources, who are not regulated but the information is in the public domain. For the avoidance of doubt Research Tree is not giving advice, nor has Research Tree validated any of the information.

Research Tree is an Appointed Representative of Sturgeon Ventures which is Authorised and Regulated by the Financial Conduct Authority.

Top
  • Home
  • Features
  • Pricing
  • Event Hub
  • Reg.News
  • Short Interest Tracker
  • Blogs
    • Academy
    • Insights
    • News
    • Research Tree
    • The Naked Fund Manager
  • Ideas & Picks
    • Ideas Hub
    • Stock Pick League
  • Explore Content
    • Regions
      • UK
      • Rest of EMEA
      • N America
      • APAC
      • LatAm
    • Exchanges
      • Aquis Apex
      • Australian Securities Exchange
      • Canadian Securities Exchange
      • Euronext Paris
      • London Stock Exchange (domestic)
      • SIX Swiss Exchange
    • Sectors
      • Automobile Industry
      • Banks
      • Building & Construction
      • Chemicals
      • Discretionary Personal Goods
      • Discretionary Retail
      • Energy
      • ETFs
      • Financial Services
      • Food & Drink
      • Food Production
      • Health
      • Household Goods & DIY
      • Industrial Equipment, Goods & Services
      • Insurance & Reinsurance
      • Investment Trusts
      • Leisure, Tourism & Travel
      • Media
      • Open-ended Funds
      • Other
      • Real Estate
      • Resources
      • Staple Retail
      • Technology
      • Telecoms
      • Trusts, ETFs & Funds
      • Utilities
    • Aic Sectors
      • Asia Pacific
      • Asia Pacific Equity Income
      • Asia Pacific Smaller Companies
      • China / Greater China
      • Commodities & Natural Resources
      • Country Specialist
      • Europe
      • European Smaller Companies
      • Flexible Investment
      • Global
      • Global Emerging Markets
      • Global Equity Income
      • Global Smaller Companies
      • Growth Capital
      • India
      • Infrastructure
      • Japan
      • Japanese Smaller Companies
      • Latin America
      • Liquidity Funds
      • North America
      • North American Smaller Companies
      • Private Equity
      • Property - Europe
      • Property - Rest of World
      • Property - UK Commercial
      • UK All Companies
      • UK Equity Income
      • UK Smaller Companies
      • VCT AIM Quoted
    • Small / Large Cap
      • UK100
      • UK250
      • UK Smallcap
      • UK Other Main Markets
      • Other
    • Private/EIS
      • EIS Single Company
      • EIS/SEIS Funds
      • IHT Products
      • SEIS Single Company
      • VCT Funds
  • Providers
    • Free/Commissioned
      • Align Research
      • BNP Paribas Exane - Sponsored Research
      • BRR Media
      • Calvine Partners
      • Capital Access Group
      • Checkpoint Partners
      • Clear Capital Markets
      • Couloir Capital
      • Edison
      • Equity Development
      • eResearch
      • Fidante Partners
      • Five Minute Pitch TV
      • goetzpartners securities Limited
      • Hardman & Co
      • Inbound Capital
      • Independent Investment Research
      • InterAxS Global
      • Kepler | Trust Intelligence
      • London Stock Exchange
      • Magnitogorsk Iron and steel works
      • Mello Events
      • piworld.co.uk
      • Proactive
      • Progressive Equity Research
      • Quantum Research Group
      • QuotedData
      • RaaS - Research as a Service
      • Radnor Capital Partners
      • Research Tree
      • SEAL Advisors Ltd
      • ShareSoc
      • Trinity Delta
      • Yellowstone Advisory
    • High Net Worth Offering
      • Fox-Davies Capital
      • Allenby Capital
      • AlphaValue
      • Alternative Resource Capital
      • Arctic Securities
      • Arden Partners
      • Auctus Advisors
      • Baptista Research
      • BNP Paribas Exane - Sponsored Research
      • Canaccord Genuity
      • Cenkos Securities
      • Couloir Capital
      • Dowgate Capital
      • finnCap
      • First Berlin
      • First Sentinel
      • Hannam & Partners
      • Hybridan
      • Liberum
      • Longspur Research
      • Louis Capital
      • Magnitogorsk Iron and steel works
      • Medley Global Advisors
      • Northland Capital Partners
      • QuotedData Professional
      • Shard Capital
      • ShareSoc
      • Shore Capital
      • Singer Capital Markets
      • SP Angel
      • Stanford Capital Partners
      • Stifel FirstEnergy
      • Stockdale Securities
      • Tamesis Partners
      • The Life Sciences Division
      • VSA Capital
      • WHIreland
      • Whitman Howard
      • Yellowstone Advisory
      • Zeus Capital
    • Institutional Offering
      • Fox-Davies Capital
      • Align Research
      • Allenby Capital
      • AlphaValue
      • Alternative Resource Capital
      • Arctic Securities
      • Arden Partners
      • Auctus Advisors
      • Baptista Research
      • BNP Paribas Exane
      • BNP Paribas Exane - Sponsored Research
      • BRR Media
      • Bryan, Garnier & Co
      • Calderwood Capital
      • Calvine Partners
      • Canaccord Genuity
      • Capital Access Group
      • Cenkos Securities
      • Checkpoint Partners
      • Clear Capital Markets
      • Couloir Capital
      • Dowgate Capital
      • Edison
      • Equity Development
      • eResearch
      • Fidante Partners
      • finnCap
      • First Berlin
      • First Sentinel
      • Five Minute Pitch TV
      • goetzpartners securities Limited
      • Hannam & Partners
      • Hardman & Co
      • Hybridan
      • Inbound Capital
      • Independent Investment Research
      • InterAxS Global
      • Kepler | Absolute Hedge
      • Kepler | Trust Intelligence
      • Liberum
      • London Stock Exchange
      • Longspur Research
      • Magnitogorsk Iron and steel works
      • Mello Events
      • Northland Capital Partners
      • Numis
      • Panmure Gordon
      • Peel Hunt
      • piworld.co.uk
      • Proactive
      • Progressive Equity Research
      • Quantum Research Group
      • QuotedData
      • RaaS - Research as a Service
      • Radnor Capital Partners
      • Research Tree
      • SEAL Advisors Ltd
      • Shard Capital
      • ShareSoc
      • Shore Capital
      • SI Capital
      • Singer Capital Markets
      • SP Angel
      • Stanford Capital Partners
      • Stifel
      • Stifel FirstEnergy
      • Stockdale Securities
      • Tamesis Partners
      • The Life Sciences Division
      • Trinity Delta
      • VSA Capital
      • WHIreland
      • Whitman Howard
      • Yellowstone Advisory
      • Zeus Capital
    • Video/Audio Interviews
      • BRR Media
      • Capital Access Group
      • Couloir Capital
      • Edison
      • Equity Development
      • Five Minute Pitch TV
      • piworld.co.uk
      • Proactive
      • QuotedData
      • RaaS - Research as a Service
      • Research Tree
      • Yellowstone Advisory
    • Event Providers
      • Capital Access Group
      • Cenkos Securities
      • Couloir Capital
      • Edison
      • Equity Development
      • Hardman & Co
      • InterAxS Global
      • Kepler | Trust Intelligence
      • London Stock Exchange
      • Mello Events
      • piworld.co.uk
      • QuotedData
      • Research Tree
      • ShareSoc
      • VSA Capital
      • Yellowstone Advisory
  • Contact
  • Sign Up
  • Sign In